

Special Issue

Advances in Metastatic Prostate Cancer

Message from the Guest Editor

In the last two decades, unprecedented improvements in the knowledge of the biology of advanced prostate cancer have led to dramatic changes in the therapeutic landscape of this disease. The disease state, formerly known as hormone-refractory, has now been defined as castration-resistant according to the central role which is covered by androgen-receptor machinery in all disease states. This has led to the development and use of androgen-receptor signaling inhibitors (ARSIs) which produce improved survival outcomes in mCRPC patients before or after docetaxel use. Docetaxel and ARSIs have been used in earlier disease states, reducing the proposed therapeutic options in the mCRPC setting. More recently, the use of PARP inhibitors and Lu-PSMA has exploited new therapeutic targets, enhancing the available options in mCRPC. These strategies, which improve patients' prognosis in late phases, are being used for testing in earlier disease states. Meanwhile, molecular imaging with new radiotracers provides more accurate disease pictures. This SI aims to highlight approaches which could improve the contemporary and future management and treatment of metastatic prostate cancer.

Guest Editor

Dr. Orazio Caffo

Department of Medical Oncology, Santa Chiara Hospital, 38112 Trento, Italy

Deadline for manuscript submissions

closed (21 April 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/178221

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)